PANCREATIC NEUROENDOCRINE TUMOUR METASTATIC

This adverse event was reported 239 times

These drugs are most commonly taken by patients reporting PANCREATIC NEUROENDOCRINE TUMOUR METASTATIC:

# Drug Count
0 EVEROLIMUS 97
1 OCTREOTIDE ACETATE 83
2 CAPECITABINE 51
3 CARBOPLATIN 30
4 ETOPOSIDE 29
5 TEMOZOLOMIDE 24
6 LUTETIUM LU 177 DOTATATE 23
7 SUNITINIB MALATE 21
8 SITAGLIPTIN 20
9 FLUOROURACIL 18
See all common drugs associated with PANCREATIC NEUROENDOCRINE TUMOUR METASTATIC

PANCREATIC NEUROENDOCRINE TUMOUR METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 STREPTOZOCIN 1 0.0043
1 LUTETIUM LU 177 DOTATATE 23 0.0040
2 METYRAPONE 3 0.0030
3 OCTREOTIDE ACETATE 83 0.0027
4 EVEROLIMUS 97 0.0020
5 BROMOCRIPTINE MESYLATE 1 0.0015
6 DIAZOXIDE 1 0.0014
7 AMILORIDE HYDROCHLORIDE 1 0.0012
8 TEMOZOLOMIDE 24 0.0011
9 PASIREOTIDE 2 0.0009
See all drugs enriched for association with PANCREATIC NEUROENDOCRINE TUMOUR METASTATIC

PANCREATIC NEUROENDOCRINE TUMOUR METASTATIC is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Adrenal Steroid Synthesis Inhibitor [EPC] 3 0.0030
1 Somatostatin Analog [EPC] 19 0.0028
2 Calcitonin [EPC] 2 0.0006
3 Topoisomerase Inhibitor [EPC] 29 0.0004
4 Provitamin D2 Compound [EPC] 9 0.0003
5 Allylamine Antifungal [EPC] 2 0.0003
6 Nucleoside Metabolic Inhibitor [EPC] 64 0.0002
7 Ergot Derivative [EPC] 1 0.0002
8 Osmotic Diuretic [EPC] 1 0.0002
9 Kinase Inhibitor [EPC] 99 0.0002
See all drug classes enriched for association with PANCREATIC NEUROENDOCRINE TUMOUR METASTATIC